How much funding has Immunic raised?

Immunic has raised $694.9M in total funding, most recently a Private Equity round.

Where is Immunic headquartered?

Immunic is headquartered in New York City, New York, United States.

What industry is Immunic in?

Immunic operates in Biotech, Healthcare.

Immunic

Q: Who are Immunic's investors?

Immunic's investors include High-Tech Grunderfonds, Boehringer Ingelheim Venture Fund, Omega Funds, Fund+.

IPO

Home - Immunic Therapeutics

Public · New York City, United States · Founded 2016 · $694.9M raised

Biotech

Healthcare

Headquarters: New York City, New York
Founded: 2016
Business Model: B2B
Website: imux.com

Total Funding: $694.9M
Last Round: $400.0M Private EquityFeb 2026
Rounds: 4
Type: Public

About

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and autoimmune diseases. Its lead program, vidofludimus calcium (IMU-838), is in Phase 3 trials for relapsing multiple sclerosis. Founded in 2016 as Immunic AG in Germany, the company redomiciled to the United States in 2019 and is headquartered in New York City.

Summary

Immunic is a Biotech company based in New York City, United States, founded in 2016. It has raised $694.9M in total across 4 rounds, most recently a $400.0M Private Equity round in Feb 2026. Investors include High-Tech Grunderfonds, Boehringer Ingelheim Venture Fund and Omega Funds.